104 related articles for article (PubMed ID: 38814086)
1. Systematic Structure-Activity Relationship Study of Nalfurafine Analogues toward Development of Potentially Nonaddictive Pain Management Treatments.
St Onge CM; Pagare PP; Zheng Y; Arriaga M; Stevens DL; Mendez RE; Poklis JL; Halquist MS; Selley DE; Dewey WL; Banks ML; Zhang Y
J Med Chem; 2024 Jun; 67(11):9552-9574. PubMed ID: 38814086
[TBL] [Abstract][Full Text] [Related]
2. Discovery of Peripheral κ-Opioid Receptor Agonists as Novel Analgesics.
Suzuki S; Sugawara Y; Inada H; Tsuji R; Inoue A; Tanimura R; Shimozono R; Konno M; Ohyama T; Higashi E; Sakai C; Kawai K
Chem Pharm Bull (Tokyo); 2017; 65(11):1085-1088. PubMed ID: 29093296
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of new opioid derivatives with a propellane skeleton and their pharmacologies: Part 5, novel pentacyclic propellane derivatives with a 6-amide side chain.
Nakajima R; Yamamoto N; Hirayama S; Iwai T; Saitoh A; Nagumo Y; Fujii H; Nagase H
Bioorg Med Chem; 2015 Oct; 23(19):6271-9. PubMed ID: 26346669
[TBL] [Abstract][Full Text] [Related]
4. Dissociable effects of the kappa opioid receptor agonist nalfurafine on pain/itch-stimulated and pain/itch-depressed behaviors in male rats.
Lazenka ML; Moerke MJ; Townsend EA; Freeman KB; Carroll FI; Negus SS
Psychopharmacology (Berl); 2018 Jan; 235(1):203-213. PubMed ID: 29063139
[TBL] [Abstract][Full Text] [Related]
5. Morphinan derivatives with an oxabicyclo[3.2.1]octane structure as dual agonists toward δ and κ opioid receptors.
Uenohara Y; Tsumura S; Hirayama S; Higashi E; Watanabe Y; Gouda H; Nagase H; Fujii H
Bioorg Med Chem; 2022 Jan; 53():116552. PubMed ID: 34894610
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and structure-activity relationship of novel opioid kappa-agonists.
Kawai K; Hayakawa J; Miyamoto T; Imamura Y; Yamane S; Wakita H; Fujii H; Kawamura K; Matsuura H; Izumimoto N; Kobayashi R; Endo T; Nagase H
Bioorg Med Chem; 2008 Oct; 16(20):9188-201. PubMed ID: 18829333
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a Potential KOR/DOR Dual Agonist with No Apparent Abuse Liability via a Complementary Structure-Activity Relationship Study on Nalfurafine Analogues.
Li M; Stevens DL; Arriaga M; Townsend EA; Mendez RE; Blajkevch NA; Selley DE; Banks ML; Negus SS; Dewey WL; Zhang Y
ACS Chem Neurosci; 2022 Dec; 13(24):3608-3628. PubMed ID: 36449691
[TBL] [Abstract][Full Text] [Related]
8. Essential structure of the κ opioid receptor agonist nalfurafine for binding to the κ receptor.
Nagase H; Fujii H
Curr Pharm Des; 2013; 19(42):7400-14. PubMed ID: 23448474
[TBL] [Abstract][Full Text] [Related]
9. Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor.
Schattauer SS; Kuhar JR; Song A; Chavkin C
Cell Signal; 2017 Apr; 32():59-65. PubMed ID: 28088389
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of 6,14-epoxymorphinan derivatives and their pharmacologies.
Nemoto T; Yamamoto N; Watanabe A; Fujii H; Hasebe K; Nakajima M; Mochizuki H; Nagase H
Bioorg Med Chem; 2011 Feb; 19(3):1205-21. PubMed ID: 21256034
[TBL] [Abstract][Full Text] [Related]
11. Involvement of GRK2 in modulating nalfurafine-induced reduction of excessive alcohol drinking in mice.
Zhou Y; Liang Y
Neurosci Lett; 2021 Aug; 760():136092. PubMed ID: 34197905
[TBL] [Abstract][Full Text] [Related]
12. Nalfurafine prevents 5'-guanidinonaltrindole- and compound 48/80-induced spinal c-fos expression and attenuates 5'-guanidinonaltrindole-elicited scratching behavior in mice.
Inan S; Dun NJ; Cowan A
Neuroscience; 2009 Sep; 163(1):23-33. PubMed ID: 19524022
[TBL] [Abstract][Full Text] [Related]
13. [Pharmacological effects of nalfurafine hydrochloride, a kappa-opioid receptor agonist].
Nakao K; Hasebe K; Yoshikawa S; Ikeda K; Hirakata M; Miyamoto Y; Mochizuki H
Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Nov; 30(5-6):185-91. PubMed ID: 21226314
[TBL] [Abstract][Full Text] [Related]
14. Discovery of highly selective κ-opioid receptor agonists: 10α-Hydroxy TRK-820 derivatives.
Suzuki S; Sugawara Y; Tsuji R; Tanimura R; Kaneko C; Yuzawa N; Yagi M; Kawai K
Bioorg Med Chem Lett; 2017 Aug; 27(16):3920-3924. PubMed ID: 28688957
[TBL] [Abstract][Full Text] [Related]
15. The Pharmacological Heterogeneity of Nepenthone Analogs in Conferring Highly Selective and Potent κ-Opioid Agonistic Activities.
Li W; Long JD; Qian YY; Long Y; Xu XJ; Wang YJ; Shen Q; Wang ZN; Yang XC; Xiao L; Sun HP; Xu YL; Chen YY; Xie Q; Wang YH; Shao LM; Liu JG; Qiu ZB; Fu W
ACS Chem Neurosci; 2017 Apr; 8(4):766-776. PubMed ID: 28033462
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the diuretic effects of chemically diverse kappa opioid agonists in rats: nalfurafine, U50,488H, and salvinorin A.
Inan S; Lee DY; Liu-Chen LY; Cowan A
Naunyn Schmiedebergs Arch Pharmacol; 2009 Mar; 379(3):263-70. PubMed ID: 18925386
[TBL] [Abstract][Full Text] [Related]
17. The kappa-opioid receptor agonist, nalfurafine, blocks acquisition of oxycodone self-administration and oxycodone's conditioned rewarding effects in male rats.
Zamarripa CA; Patel TR; Williams BC; Pareek T; Schrock HM; Prisinzano TE; Freeman KB
Behav Pharmacol; 2020 Dec; 31(8):792-797. PubMed ID: 32804774
[TBL] [Abstract][Full Text] [Related]
18. Discovery of attenuation effect of orexin 1 receptor to aversion of nalfurafine: Synthesis and evaluation of D-nor-nalfurafine derivatives and analyses of the three active conformations of nalfurafine.
Nagumo Y; Katoh K; Iio K; Saitoh T; Kutsumura N; Yamamoto N; Ishikawa Y; Irukayama-Tomobe Y; Ogawa Y; Baba T; Tanimura R; Yanagisawa M; Nagase H
Bioorg Med Chem Lett; 2020 Sep; 30(17):127360. PubMed ID: 32738987
[TBL] [Abstract][Full Text] [Related]
19. The effect of 17-N substituents on the activity of the opioid κ receptor in nalfurafine derivatives.
Nemoto T; Yamamoto N; Wada N; Harada Y; Tomatsu M; Ishihara M; Hirayama S; Iwai T; Fujii H; Nagase H
Bioorg Med Chem Lett; 2013 Jan; 23(1):268-72. PubMed ID: 23200250
[TBL] [Abstract][Full Text] [Related]
20. Phosphoproteomic approach for agonist-specific signaling in mouse brains: mTOR pathway is involved in κ opioid aversion.
Liu JJ; Chiu YT; DiMattio KM; Chen C; Huang P; Gentile TA; Muschamp JW; Cowan A; Mann M; Liu-Chen LY
Neuropsychopharmacology; 2019 Apr; 44(5):939-949. PubMed ID: 30082888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]